As part of Myeloma Patients Europe’s (MPE) ongoing work to ensure that the patient voice is fully represented and to strengthen organisations’ and individuals’ ability to advocate effectively, in 2017, MPE created the Advocate Development Programme (ADP). The ADP is a 12-month training programme designed to develop participants’ advocacy knowledge and skills to serve patients better locally, nationally and across Europe. Through the course, participants improve their understanding of clinical research and development, mechanisms of accessing diagnostics and drugs, interaction with stakeholders, including clinicians and industry, and the basics of evidence-based advocacy.
Katie Joyner, Co-Chief Executive Officer (CEO) at MPE, and two ADP participants, Fionnuala Duffy and Vincent Claus, explain in this video the main objectives and details of this programme:
The ADP combines virtual and in-person lectures to educate advocates on the disease and treatment of myeloma and AL amyloidosis, as well as the entire drug development process. Participants will understand the research, development and regulatory processes, and how advocates can influence and shape these to improve patient experiences and outcomes. In addition to monthly sessions, the programme includes participation in important myeloma scientific meetings in Europe (attendance sponsored by MPE) such as the European Haematology Association (EHA) Annual Meeting and the European Cancer Organisation Summit.
The MPE ADP limits cohort size (6 – 8 participants) to ensure an engaging learning environment and individual support. This programme is a unique opportunity to build your advocacy skills, while learning from experts and networking with peers.
Who should apply for the ADP?
Patients, carers, advocates and community members, who are interested in developing professional advocacy skills in the fields of myeloma and AL amyloidosis, and who are committed to improving outcomes for patients across Europe.
The deadline to apply for the MPE ADP 2024 is over.